Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-110 + Erlotinib in Advanced NSCLC
NCT01504542Phase 2Withdrawn
- Sponsor
- NightHawk Biosciences, Inc.
- Start
- Dec 2011
- Primary completion
- Dec 2013
- Modality
- Prophylactic Vaccines, Cell Therapies, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of viagenpumatucel-L in non-small cell lung cancer (NSCLC), sponsored by NightHawk Biosciences, Inc.. Planned start Dec 2011; status: withdrawn.
02
Drugs
viagenpumatucel-L
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT01504542.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01504542.